No products in the cart.
Rabbit Polyclonal Phospho-Catenin-beta (S33) antibody (STJ90206)
Supplier: St John’s Laboratory Ltd.
Recommended applications: IHC, IF, ELISA
Recommended dilution: IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000;
Recommended protocols: check protocols
Click or hover above images to see image description for Catenin-beta (phospho Ser33) Polyclonal Antibody.
Check alternative names for the antibodyExpand
CTNNB1 antibody, CTNNB antibody, OK/SW-cl.35 antibody, PRO2286 antibody,|Beta catenin antibody|Beta-catenin antibody|Cadherin associated protein antibody|Catenin (cadherin associated protein), beta 1, 88kDa antibody|Catenin beta 1 antibody|Catenin beta-1 antibody|CATNB antibody|CHBCAT antibody|CTNB1_HUMAN antibody|CTNNB antibody|CTNNB1 antibody|DKFZp686D02253 antibody|FLJ25606 antibody|FLJ37923 antibody|OTTHUMP00000162082 antibody|OTTHUMP00000165222 antibody|OTTHUMP00000165223 antibody|OTTHUMP00000209288 antibody|OTTHUMP00000209289 antibody|Anti-beta Catenin antibody
SCBT cat No: sc-65480|sc-59737|sc-53483|sc-53484|sc-515105|sc-393501|sc-376841|sc-59896|sc-59897|sc-1496|sc-69763|sc-133239|sc-133238|sc-31001|sc-515074|sc-7963|sc-376959|sc-133240|sc-7199|sc-376805|sc-31000|sc-133452|sc-23167|sc-13332|sc-22745|sc-20797|
Catenin-beta (phospho Ser33) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-Catenin-beta (S33) Polyclonal Antibody detects endogenous levels of Catenin-beta protein only when phosphorylated at S33.
Synthesized phospho-peptide derived from Catenin-beta (phospho Ser33) at AA range 10-90
IHC, IF, ELISA
|Recommended dilution|| |
IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000;
|Molecular weight|| |
Catenin-beta (phospho Ser33) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Catenin-beta (phospho Ser33) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Catenin beta-1 antibody, Beta-catenin antibody
|Protein names|| |
Catenin beta-1 , Beta-catenin
|Protein function|| |
Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML . Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle (By similarity).
|Protein tissue specificity|| |
Expressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon. Present in cortical neurons (at protein level).
|Involvement in disease|| |
Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. . Note: The gene represented in this entry may be involved in disease pathogenesis.; Note: Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.; Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. . Note: The gene represented in this entry is involved in disease pathogenesis.; Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. . Note: The gene represented in this entry may be involved in disease pathogenesis.; Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Note: A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.; Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. . Note: The gene represented in this entry may be involved in disease pathogenesis.; Mental retardation, autosomal dominant 19 (MRD19) [MIM:615075]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD19 features include severe intellectual disability with absent or very limited speech, microcephaly, and spasticity which severely impaired the ability to walk. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the beta-catenin family. / Contains 12 ARM repeats.
|Protein post-translational modifications|| |
Phosphorylation at Ser-552 by AMPK promotes stabilizion of the protein, enhancing TCF/LEF-mediated transcription (By similarity). Phosphorylation by GSK3B requires prior phosphorylation of Ser-45 by another kinase. Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33. Phosphorylated by NEK2. EGF stimulates tyrosine phosphorylation. Phosphorylation on Tyr-654 decreases CDH1 binding and enhances TBP binding. Phosphorylated on Ser-33 and Ser-37 by HIPK2. This phosphorylation triggers proteasomal degradation. Phosphorylation on Ser-191 and Ser-246 by CDK5. Phosphorylation by CDK2 regulates insulin internalization. Phosphorylation by PTK6 at Tyr-64, Tyr-142, Tyr-331 and/or Tyr-333 with the predominant site at Tyr-64 is not essential for inhibition of transcriptional activity. / Ubiquitinated by the SCF(BTRC) E3 ligase complex when phosphorylated by GSK3B, leading to its degradation. Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent proteasomal degradation (By similarity). / S-nitrosylation at Cys-619 within adherens junctions promotes VEGF-induced, NO-dependent endothelial cell permeability by disrupting interaction with E-cadherin, thus mediating disassembly adherens junctions. / O-glycosylation at Ser-23 decreases nuclear localization and transcriptional activity, and increases localization to the plasma membrane and interaction with E-cadherin CDH1. / Deacetylated at Lys-49 by SIRT1.
|Protein cellular localization|| |
Cytoplasm / Nucleus / Cytoplasm > cytoskeleton / Cell junction > adherens junction / Cell junction / Cell membrane / Cytoplasm > cytoskeleton > microtubule organizing center > centrosome / Cytoplasm > cytoskeleton > spindle pole
AntibodyPlus can customize Catenin-beta (phospho Ser33) Antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: